An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center
Don’t let your disease define you
May 28th 2021, 1:00pm
Researchers observed no difference in overall and progression-free survival in patients with mantle cell lymphoma who started high-intensity treatment at least 90 days after receiving a diagnosis compared with a non-intensive therapy approach.
May 5th 2021, 1:00pm
Factors including progression-free survival, duration of response and overall survival were promising at 15 months in patients with relapsed/refractory mantle cell lymphoma.
April 28th 2021, 12:30pm
April 28th 2021, 12:15pm
Navigating life with blood cancer
April 9th 2021, 9:00pm
A high intensity immunochemotherapy with maintenance therapy led to 93.2% of patients achieving a complete response and 55.6% of patients with progression-free survival at five years.
April 8th 2021, 9:00pm
Researchers found that patients who were never married, had lower educational levels or had comorbidities were less likely to be suggested an autologous hematopoietic cell transplantation, which may underline a need for more informed decision making.
April 6th 2021, 1:00pm
Pirtobrutinib was safe and effective in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinemia, some of whom developed intolerance or resistance to previous covalent BTK inhibitors.
March 17th 2021, 12:00pm
February 16th 2021, 10:00pm
A meta-analysis found that minimal residual disease positivity after a particular treatment for mantle cell lymphoma can predict worse survival benefit.
December 29th 2020, 7:00pm
A roundup of some of the most read news and updates in mantle cell lymphoma in 2020 from CURE®.
A Milkshake and Metastatic Cancer
Fighting Hard for Patients with Fibrolamellar Carcinoma
Masking in a ‘Post-Pandemic’ World
A Guardian Angel Among Doctors
